Sign In
Buy KZIA
$10.95
-0.84 (-7.12%)
At Close: Jun 03, 2026
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
02:30pm, Friday, 07'th Aug 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
02:30pm, Monday, 22'nd Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of p
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
04:39am, Monday, 22'nd Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of p
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
02:30pm, Monday, 01'st Jun 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of
Even if it's not a huge purchase, we think it was good to see that Iain Ross, the Independent Chairman of the Board of...
Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?
04:49am, Monday, 25'th May 2020
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
NLY, NRZ among premarket gainers
01:20pm, Wednesday, 08'th Apr 2020
Ellington Financial (NYSE:EFC) +54% as book value holds up.New York Mortgage Trust (NASDAQ:NYMT) +39% on updating on financing, portfolio.Myomo (NYSEMKT:MYO) +26% on accelerating growth in pipeline
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
12:00pm, Tuesday, 07'th Apr 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (forme
Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?
09:34pm, Monday, 24'th Feb 2020
James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...
Edison issues ADR update on Kazia Therapeutics (KZIA)
12:55pm, Monday, 13'th Jan 2020
LONDON, UK / ACCESSWIRE / January 13, 2020 / Kazia Therapeutics (NASDAQ:KZIA) has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
03:00pm, Wednesday, 11'th Dec 2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE,
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
01:45pm, Monday, 02'nd Dec 2019
LONDON, UK / ACCESSWIRE / December 2, 2019 / Kazia Therapeutics (NASDAQ:KZIA) has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data a
If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
10:12pm, Thursday, 28'th Nov 2019
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
03:00pm, Monday, 25'th Nov 2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 i
Kazia Raises A$4.0 Million to Progress R&D Programs
02:16am, Monday, 28'th Oct 2019
NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to i
